Lung cancer is globally recognized as a big killer and it is undoubtedly a leading cause of cancer deaths in Europe and in the world. Researchers provide evidence of advancements which lead to continuous considerable improvements in possible treatments of lung cancer and offer valuable contributions to change the political and social environment for more pro-active prevention initiatives.

Organized as a joint effort between the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), the European Lung Cancer Conference will be held biennially, alternating with the World Conference on Lung Cancer and the ESMO chest tumors conference. The event will gather top multidisciplinary experts to provide the audience (European and worldwide) with state-of-the-art education as well as with the most recent research data on both the most common and uncommon types of lung cancer.

Meeting highlights:

* The future of imaging

* IASLC staging report of lung cancer

* Advances in surgical techniques for in-situ carcinoma

* Controversies on new radiotherapy techniques associated to surgery

* Novel curative treatments for early disease

* Targeted therapies and selection of patients on genomic analyses

* Toxicity management

* Identification of new diseases: is adenocarcinoma a cancer or not?

* Tobacco policy

Among the top international experts that have contributed to this unique conference: David Beer, US; Paul A. Bunn, US; Jim Cox, US; Jeffrey Engelman, US; David Gandara, US; Heine H. Hansen, DK; David Jablons, US; François Mornex, FR (Conference Co-Chair); Joseph Nevins, US; Rafael Rosell, ES (Conference Co-Chair); Nagahiro Saijo, JP; Frances A. Shepherd, CA; Robert Timmermann, US; William Travis, US; Andrew Turrisi, US



Click here to access the full conference program.

Source: Vanessa Pavinato
European Society for Medical Oncology